RxDoctor Payments Data

Jamie Becker

Psychiatric/Mental Health · Lawrenceburg, INNPI 1982127205

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 45 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$362
  • Revance Therapeutics, Inc.$137
  • E.r. Squibb & Sons, L.L.C.$102
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$87
  • Otsuka America Pharmaceutical, Inc.$79
  • Johnson & Johnson$38
  • plus $202 from 8 others

What the payments were for

  • Food & beverage$90690%
  • Education$10110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,008 in reported general payments places this provider in the 60th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$9,838
Medicare patients
30
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$134,697
Abilify MaintenaAripiprazole20$57,245
VraylarCariprazine Hcl36$49,343
CaplytaLumateperone Tosylate13$37,377
RexultiBrexpiprazole20$26,091
TrintellixVortioxetine Hydrobromide26$14,363
Lurasidone Hcl26$9,630
Paliperidone ErPaliperidone18$5,928
Desvenlafaxine Succinate ErDesvenlafaxine Succinate40$4,633
VyvanseLisdexamfetamine Dimesylate12$4,579
Clozapine55$4,076
Aripiprazole49$3,572
Asenapine Maleate13$2,664
Vilazodone Hcl24$2,446
Amitriptyline Hcl70$2,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$38$134,69740 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$79$83,33640 claims
AbbVieVraylar$362$49,34336 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$87$37,37713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Lawrenceburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →